Your browser is no longer supported. Please, upgrade your browser.
Settings
ANNX [NASD]
Annexon, Inc.
Index- P/E- EPS (ttm)-3.03 Insider Own0.30% Shs Outstand38.34M Perf Week14.96%
Market Cap638.19M Forward P/E- EPS next Y-3.70 Insider Trans-29.02% Shs Float36.13M Perf Month-6.53%
Income-116.10M PEG- EPS next Q-1.02 Inst Own99.04% Short Float4.76% Perf Quarter-8.16%
Sales- P/S- EPS this Y14.60% Inst Trans-1.91% Short Ratio6.91 Perf Half Y-31.49%
Book/sh6.90 P/B2.28 EPS next Y1.90% ROA-34.90% Target Price38.20 Perf Year-36.70%
Cash/sh6.70 P/C2.35 EPS next 5Y38.60% ROE-37.90% 52W Range13.03 - 38.01 Perf YTD-37.08%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.56% Beta-
Dividend %- Quick Ratio23.10 Sales past 5Y- Gross Margin- 52W Low17.96% ATR1.33
Employees62 Current Ratio23.10 Sales Q/Q- Oper. Margin- RSI (14)46.57 Volatility9.21% 9.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-20.10% Profit Margin- Rel Volume0.84 Prev Close15.75
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume248.90K Price15.37
Recom1.70 SMA200.47% SMA50-12.38% SMA200-28.86% Volume92,783 Change-2.41%
Nov-30-21Initiated H.C. Wainwright Buy $40
Sep-23-21Initiated Cantor Fitzgerald Overweight $40
Jan-26-21Initiated Needham Buy $37
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
Nov-30-21 05:24AM  
Nov-28-21 11:17AM  
Nov-09-21 04:01PM  
Oct-19-21 06:38AM  
Oct-04-21 10:49AM  
06:30AM  
Sep-23-21 06:30AM  
Sep-20-21 06:30AM  
Sep-16-21 11:30AM  
Aug-16-21 04:01PM  
Jul-22-21 07:00AM  
May-21-21 06:30AM  
May-17-21 04:05PM  
May-05-21 07:00AM  
Apr-22-21 01:47AM  
Mar-25-21 07:00AM  
Mar-01-21 01:11PM  
07:00AM  
Feb-08-21 07:00AM  
Jan-12-21 07:00AM  
Jan-05-21 07:00AM  
Dec-21-20 07:00AM  
Dec-11-20 01:15PM  
Nov-16-20 04:01PM  
Nov-12-20 04:05PM  
Oct-24-20 10:13AM  
Sep-08-20 04:01PM  
Jul-30-20 08:00AM  
Jul-28-20 04:05PM  
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Love DouglasPresident & CEONov 11Option Exercise1.54100,942155,503100,942Nov 15 06:05 PM
Love DouglasPresident & CEOSep 16Option Exercise1.417,50010,5727,500Sep 20 05:46 PM
Love DouglasPresident & CEOSep 16Sale22.057,500165,3400Sep 20 05:46 PM
Lew JenniferEVP & Chief Financial OfficerSep 13Option Exercise7.493,50026,2105,500Sep 15 06:35 PM
Yednock TedEVP & Chief Scientific OfficerSep 13Option Exercise1.6816,19027,22516,190Sep 15 06:35 PM
Yednock TedEVP & Chief Scientific OfficerSep 13Sale20.0016,190323,8600Sep 15 06:35 PM
Lew JenniferEVP & Chief Financial OfficerSep 13Sale20.013,50070,0342,000Sep 15 06:35 PM
Love DouglasPresident & CEOJun 08Option Exercise1.413,7505,2863,750Jun 09 04:32 PM
Love DouglasPresident & CEOJun 08Sale22.553,75084,5620Jun 09 04:32 PM
Love DouglasPresident & CEOJun 07Option Exercise1.413,7505,2863,750Jun 09 04:32 PM
Love DouglasPresident & CEOJun 07Sale22.313,75083,6670Jun 09 04:32 PM
Yednock TedEVP & Chief Scientific OfficerJun 03Option Exercise1.4115,00021,14415,000Jun 07 04:47 PM
Yednock TedEVP & Chief Scientific OfficerJun 03Sale21.4915,000322,3250Jun 07 04:47 PM
Lew JenniferEVP & Chief Financial OfficerMay 27Option Exercise7.493,50026,2105,500Jun 01 06:01 PM
Lew JenniferEVP & Chief Financial OfficerMay 27Sale22.243,50077,8352,000Jun 01 06:01 PM
Love DouglasPresident & CEOApr 01Option Exercise1.41500705500Apr 02 12:31 PM
Love DouglasPresident & CEOApr 01Sale28.0850014,0410Apr 02 12:31 PM
Love DouglasPresident & CEOMar 31Option Exercise1.417,10210,0117,102Apr 02 12:31 PM
Love DouglasPresident & CEOMar 31Sale28.117,102199,6210Apr 02 12:31 PM
Love DouglasPresident & CEOMar 30Option Exercise1.413,7505,2863,750Mar 31 04:04 PM
Love DouglasPresident & CEOMar 30Sale24.523,75091,9660Mar 31 04:04 PM
Love DouglasPresident & CEOMar 29Option Exercise1.413,7505,2863,750Mar 31 04:04 PM
Love DouglasPresident & CEOMar 29Sale25.423,75095,3340Mar 31 04:04 PM
Yednock TedEVP & Chief Scientific OfficerMar 25Option Exercise1.6816,17527,14816,175Mar 29 05:10 PM
Yednock TedEVP & Chief Scientific OfficerMar 25Sale28.8016,175465,7700Mar 29 05:10 PM
Keswani SanjayEVP & Chief Medical OfficerMar 24Option Exercise7.493,99529,9173,995Mar 26 05:52 PM
Keswani SanjayEVP & Chief Medical OfficerMar 24Sale30.173,995120,5120Mar 26 05:52 PM
Lew JenniferEVP & Chief Financial OfficerMar 23Option Exercise7.495,00037,4427,000Mar 25 07:31 PM
Lew JenniferEVP & Chief Financial OfficerMar 23Sale28.445,000142,1762,000Mar 25 07:31 PM